Moyses Zenaide Providello, Nakandakari Fausto Kigui, Magaldi Antonio José
Laboratório de Pesquisa Básica-LIM 12, Laboratórios de Investigação Médica-Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil.
Nephrol Dial Transplant. 2008 Apr;23(4):1173-8. doi: 10.1093/ndt/gfm714. Epub 2007 Dec 8.
The pathogenesis of hyponatraemia caused by fluoxetine(Fx) use in the treatment of depression is not well understood. It has been attributed to a SIADH, although ADH-enhanced plasma level has not yet been demonstrated in all the cases reported in humans. This experiment aimed at investigating the effect of fluoxetine on the kidney and more specifically in the inner medullary collecting duct (IMCD).
(1) In vivo study: (a) 10 rats were injected daily i.p. with 10 mg/kg fluoxetine doses. After 10 days, rats were sacrificed and blood and kidneys were collected. (b) Immunoblotting studies for AQP2 protein expression in the IMCD from injected rats and in IMCD tubules suspension from 10 normal rats incubated with 10(-7) M fluoxetine. (2) In vitro microperfusion study: The osmotic water permeability (P(f), mum/s) was determined in normal rats IMCD (n = 6), isolated and perfused by the standard methods.
In vivo study: (a) Injected rats with fluoxetine lost about 12% body weight; Na(+) plasma level decreased from 139.3 +/- 0.78 mEq/l to 134.9 +/- 0.5 mEq/l (p < 0.01) and K(+) and ADH plasma levels remained unchanged. (b) Immunoblotting densitometric analysis of the assays showed an increase in AQP2 protein abundance of about 40%, both in IMCDs from injected rats [control period (cont) 99.6 +/- 5.2 versus Fx 145.6 +/- 16.9, p < 0.05] and in tubule suspension incubated with fluoxetine (cont 100.0 +/- 3.5 versus 143.0 +/- 2.0, p < 0.01). In vitro microperfusion study fluoxetine increased P(f) in the IMCD in the absence of ADH from the cont 7.24 +/- 2.07 to Fx 15.77 +/- 3.25 (p < 0.01).
After fluoxetine use, the weight and plasma Na(+) level decreased, and the K(+) and ADH plasma levels remained unchanged, whereas the AQP2 protein abundance and water absorption in the IMCD increased, leading us to conclude that the direct effect of fluoxetine in the IMCD could explain at least in part, the hyponatraemia found sometime after this drug use in humans.
氟西汀(Fx)用于治疗抑郁症时导致低钠血症的发病机制尚不完全清楚。虽然在所有人类报告病例中尚未证实抗利尿激素(ADH)水平升高,但一直认为其与抗利尿激素分泌异常综合征(SIADH)有关。本实验旨在研究氟西汀对肾脏的影响,更具体地说是对肾内髓集合管(IMCD)的影响。
(1)体内研究:(a)10只大鼠每天腹腔注射10mg/kg氟西汀。10天后,处死大鼠并采集血液和肾脏。(b)对注射大鼠的IMCD以及10只正常大鼠的IMCD小管悬浮液与10⁻⁷M氟西汀孵育后的AQP2蛋白表达进行免疫印迹研究。(2)体外微灌注研究:采用标准方法分离并灌注正常大鼠的IMCD(n = 6),测定其渗透水通透性(P(f),μm/s)。
体内研究:(a)注射氟西汀的大鼠体重减轻约12%;血浆Na⁺水平从139.3±0.78mEq/l降至134.9±0.5mEq/l(p < 0.01),而血浆K⁺和ADH水平保持不变。(b)免疫印迹密度分析显示,注射大鼠的IMCD(对照期(cont)99.6±5.2 vs Fx 145.6±16.9,p < 0.05)以及与氟西汀孵育的小管悬浮液(cont 100.0±3.5 vs 143.0±2.0,p < 0.01)中AQP2蛋白丰度均增加约40%。体外微灌注研究表明,在无ADH的情况下,氟西汀使IMCD中的P(f)从对照值7.24±2.07增加至Fx值15.77±3.25(p < 0.01)。
使用氟西汀后,体重和血浆Na⁺水平降低,但血浆K⁺和ADH水平保持不变,而IMCD中的AQP2蛋白丰度和水吸收增加,这使我们得出结论,氟西汀在IMCD中的直接作用至少可以部分解释人类使用该药物后有时出现的低钠血症。